• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

What I Would Tell the Woman I Was Before Breast Cancer

by MM360 Staff | May 26, 2025 | Uncategorized

Source: CureToday articles After being diagnosed with breast cancer at 39, I learned to advocate for myself, transforming fear into fierce resolve and purpose through every step. Read More

Finding Peace Beyond Caregiving and Oncology

by MM360 Staff | May 26, 2025 | Uncategorized

Source: CureToday articles I reflect on my journey from caregiver to advocate, embracing a future shaped by cancer but no longer defined by it. Read More

Understanding Unique Challenges AYA Patients With Cancer Face

by MM360 Staff | May 26, 2025 | Uncategorized

Source: CureToday articles Dr. Andrew M. Evens discusses long-term survivorship challenges that can occur among adolescent and young lymphoma survivors. Read More

IDH Inhibitors Offer New, Safer Option for Some Brain Tumors

by MM360 Staff | May 25, 2025 | Uncategorized

Source: CureToday articles IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell. Read More

What I Learned From My Cancer Nurse Maria

by MM360 Staff | May 25, 2025 | Uncategorized

Source: CureToday articles Maria, my oncology nurse, inspired lasting change in my life through compassion, wisdom and faith during my cancer surgery and recovery. Read More

Helping the Team While Helping Others

by MM360 Staff | May 24, 2025 | Uncategorized

Source: CureToday articles Kathleen Shuey, M.S., RN, SCON, ACNS-BC, listens and guides us in the right direction in caring for our oncology population. Read More
« Older Entries
Next Entries »

Recent Content

  • Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy
  • Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation
  • Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
  • Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma
  • Pancreatic cancer treatment atebimetinib set for Phase 3 trial
  • Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells
  • 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
  • (no title)
  • New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT